

## Addendum

**Addendum: Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series****Mark Chang<sup>1</sup>, Wolfram Samlowski<sup>2,3,4</sup> and Raul Meoz<sup>2,3</sup>**<sup>1</sup>University Medical Center of Southern Nevada, Las Vegas, NV 89102, USA<sup>2</sup>Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA<sup>3</sup>Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA<sup>4</sup>Department of Internal Medicine, University of Nevada, Reno, NV 89557, USA**Published:** August 10, 2023**Copyright:** © 2023 Chang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** No external funding was procured for this research.Original article: Oncotarget. 2023; 14:709–718. <https://doi.org/10.18632/oncotarget.28470>